Clinical Trials Logo

Clinical Trial Summary

This single institution, phase I clinical trial will determine the safety and feasibility of employing T-cell receptor (TCR) αβ+ and CD19+ (Cluster of Differentiation ) depleted hematopoietic stem cell transplantation (HSCT) using peripheral blood stem cells (PBMC) from closely matched unrelated donors or haploidentical donors to treat non-malignant hematologic diseases in children and young adults. Allogeneic hematopoietic stem cell transplantation has become a curative option for children and adolescents with a variety of otherwise fatal conditions. To reduce the incidence and severity of graft-versus-host disease (GVHD) associated with allogeneic hematopoietic stem cell transplantation, donor grafts are depleted of T cells, either using CD34+ selection or CD3+/CD19+ depletion of grafts. However, these selection processes also deplete the graft of protective cell subsets, such as γδ T cells, natural killer(NK) cells, monocytes and dendritic cells, which play important roles in the immune response to infectious agents. Moreover, the presence of NK cells and γδ T in donor grafts is associated with more rapid immune reconstitution after HSCT transplantation. In order to retain these protective immune cell subsets, this trial will use a novel, highly selective graft engineering process using the Miltenyi CliniMACS system that selectively depletes αβ-T cells and B cells which are responsible for GVHD and Epstein Barr Virus (EBV)-related post-transplantation lymphoproliferative disorder, respectively. Prior to transplantation, patients will be treated with a conditioning regimen, specific for the original disorder. The primary objective of this study is evaluation of the safety and feasibility of HSCT using TCRαβ+/CD19+ depleted hematopoietic stem cells to treat non-malignant hematologic diseases. This will be assessed by evaluating the incidence of graft failure, grade III-IV acute GVHD and chronic GVHD and TRM. Secondary objectives include the evaluation of immune reconstitution and incidence of post-transplant infections, adverse events, serious adverse events, overall and disease-free survival and the efficiency of graft processing by the CliniMACS System.


Clinical Trial Description

n/a


Study Design


Related Conditions & MeSH terms


NCT number NCT04806347
Study type Interventional
Source University of Wisconsin, Madison
Contact Jenny Weiland
Phone 608-890-8070
Email PedsHemOncResearch@lists.wisc.edu
Status Not yet recruiting
Phase Phase 1
Start date August 2024
Completion date May 2029

See also
  Status Clinical Trial Phase
Recruiting NCT00106015 - Diamond Blackfan Anemia Registry (DBAR)
Completed NCT00059293 - Transcranial Doppler (TCD) Ultrasound of Subjects Enrolled in BABY HUG - Ancillary to BABY HUG
Completed NCT00023530 - Blood and Marrow Transplant Clinical Research Network N/A
Not yet recruiting NCT05983536 - The Evaluation of Anti-interference Ability and Clinical Specificity of HIV Ag +Ab Assay Kit (Sysmex)
Recruiting NCT03548766 - Using DNA-Typing and Erythrocyte Microparticle Analysis to Detect Blood Doping Phase 3
Completed NCT00007371 - Hepatitis C in Clinically Discordant Hemophilic Siblings N/A
Completed NCT00000587 - Erythropoietin for Anemia Due to Zidovudine in Human Immunodeficiency Virus Infection Phase 2
Completed NCT00005682 - Aplastic Anemia Epidemiology: Incidence and Case-control N/A
Completed NCT00005305 - Hepatitis Delta Infections in Hemophiliacs N/A
Completed NCT00005304 - Delta Hepatitis and Liver Disease in Hemophiliacs
Completed NCT00005277 - Cooperative Study of The Clinical Course of Sickle Cell Disease N/A
Completed NCT00035763 - Pain in Sickle Cell Epidemiologic Study N/A
Completed NCT00005300 - Investigation of Selected Patient Groups From The Cooperative Study of Sickle Cell Disease N/A
Recruiting NCT04600609 - Examining the Experiences of Children With Blood Disorders
Not yet recruiting NCT03881917 - Cystatin c and Beta 2 Microglobulin in Thalassemic Children.
Completed NCT00005556 - Retention of Bone Marrow Donors in a National Registry N/A
Completed NCT00000597 - Multi-Center Trial of Anti-Thymocyte Globulin in Treatment of Aplastic Anemia and Other Hematologic Disorders Phase 3
Completed NCT03586180 - Medical Clowning: Needs Assessment and Implication for Hospitalized Children With Cancer/Blood Disease
Recruiting NCT03848962 - Collection and Distribution of Biospecimens for Novel Research Uses
Terminated NCT00486720 - Phase IIa Vorinostat (MK0683, Suberoylanilide Hydroxamic Acid (SAHA)) Study in Lower Risk Myelodysplastic Syndromes (0683-064) Phase 2